Objective The purpose of our study was to evaluate the prognostic value of platelet reactivity, initial level of inflammation markers and endothelial dysfunction, as well as CYP2C19*2 allele carriage in…
Objective We aimed to determine different laboratory and genetic factors impact on high on-treatment platelet reactivity (HOPR) on dual antiplatelet therapy (DAPT). Methods Our study included 94 patients with SCAD…
Objective We aimed to evaluate the risk factors of ischemic events in patients with stable CAD in the preoperative and postoperative period during percutaneous coronary intervention according to laboratory data…
Objectives Bioresorbable vascular scaffold system (BVS) is the latest, fully absorbable vascular therapy system which is used to treat coronary artery disease. BVS has been used in different coronary lesion…
Objectives The present study aimed to evaluate the late term changes in radial artery luminal diameter (RAD) and vasodilatation response following transradial coronary intervention (TRI). Background TRI inducing a trauma…
Background Chronic heart failure is a common health problem with poor prognosis, high mortality rate and the incidence of this disease is increasing continuously. Prognosis of chronic systolic heart failure…
Aim NTproBNP is a serum biomarker of congestive heart failure (CHF) that is originated from ventricles due to myocardial stretch. Galectin is a novel serum biomarker of myocardial fibrosis and…
Background In addition to the conventional treatment by drugs, the CRT has proven its effectiveness for survival and quality of life in patients (pts) with congestive heart failure. Objectives The…
Objectives We aimed to evaluate the correlation between the pre-procedural serum lipid levels and the extent of periprocedural myocardial injury (PMI) in patients undergoing elective percutaneous coronary intervention (PCI). Background…
Objective It has been aimed to investigate the Galectin-3 (GAL-3) levels and clinical responses after addition of spironolactone as a mineralocorticoid receptor antagonist (MRA) to the current treatment in patients…
